The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma

被引：0
|
作者：
Seiden, Emily E.
Richardson, Spencer M.
Ramnath, Shrey
Whiteside, Tia
Coy, Kathryn L.
Sinn, Anthony L.
Capitano, Maegan L.
Pollok, Karen E.
Collier, Chris D.
Greenfield, Ed M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7554
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Exposure-QTc Response Analysis of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin
    Godfrey, C. J.
    Cabell, Christopher H.
    Balser, Barbara
    Wolfson, Julie
    Nichols, Jean
    Burris, Howard A., III
    BLOOD, 2011, 118 (21) : 1151 - 1151
  • [32] Resistance to the histone deacetylase inhibitor romidepsin is associated with degradation of Bim following MAPK pathway activation
    Chakraborty, Arup R.
    Robey, Rob
    Zhan, Zhirong
    Luchenko, Victoria
    Gottesman, Michael
    Collie, Nathan
    Gillet, Jean-Pierre
    Piekarz, Richard
    Kossenkov, Andrew
    Showe, Louise
    Bates, Susan
    CANCER RESEARCH, 2013, 73 (08)
  • [33] Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)
    Parker, C.
    Molife, R.
    Karavasilis, V.
    Reid, A.
    Patterson, S. G.
    Riggs, C.
    Higano, C.
    Stadler, W. M.
    McCulloch, W.
    de Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
    Feng, Wan
    Zhang, Bin
    Cai, Dawei
    Zou, Xiaoping
    CANCER LETTERS, 2014, 347 (02) : 183 - 190
  • [35] Therapeutic potential of histone deacetylase inhibitors in human liposarcomas
    Muhlenberg, Thomas
    Pedeutour, Florence
    Fletcher, Jonathan A.
    Schuler, Martin
    Bauer, Sebastian
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [36] A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
    Selim, Omar
    Song, Clara
    Kumar, Amy
    Phelan, Rebecca
    Singh, Arun
    Federman, Noah
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [37] MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
    Chakraborty, Arup R.
    Robey, Robert W.
    Luchenko, Victoria L.
    Zhan, Zhirong
    Piekarz, Richard L.
    Gillet, Jean-Pierre
    Kossenkov, Andrew V.
    Wilkerson, Julia
    Showe, Louise C.
    Gottesman, Michael M.
    Collie, Nathan L.
    Bates, Susan E.
    BLOOD, 2013, 121 (20) : 4115 - 4125
  • [38] Histone deacetylase: A potential therapeutic target for ovarian dysfunction
    Sunita
    Singh, Pankaj Kumar
    Onteru, Suneel Kumar
    Singh, Dheer
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2018, 23 : 512 - 534
  • [39] Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
    Jiang, Li-Ping
    Yu, Xiao-Hua
    Chen, Jin-Zhi
    Hu, Mi
    Zhang, Yang-Kai
    Lin, Hui-Ling
    Tang, Wan-Ying
    He, Ping-Ping
    Ouyang, Xin-Ping
    AGING AND DISEASE, 2022, 13 (03): : 773 - 786
  • [40] Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
    Pang, Maoyin
    Zhuang, Shougang
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 335 (02): : 266 - 272
12345